Clearmind Medicine (US:CMND) Benzinga·2025-11-26 09:32Core Insights - Clearmind Medicine Inc. (NASDAQ:CMND) experienced a 7.09% increase in pre-market trading, reaching a price of $0.1713 after closing at $0.16, which was a decline of 19.4% on the previous day [1][6]. Group 1: Clinical Trial Developments - The company announced that Tel Aviv Sourasky Medical Center (TASMC) has enrolled the first participant in its multinational Phase I/IIa clinical trial of CMND-100 for alcohol use disorder, which has received approval from the U.S. Food and Drug Administration [2]. - TASMC is part of an expanded trial network that includes Yale School of Medicine, Johns Hopkins University School of Medicine, and Hadassah Medical Center for patient screening and enrollment [3]. - The Phase I/IIa trial is designed to assess the pharmacokinetics, safety, tolerability, and initial efficacy of CMND-100, an oral MEAI-based medication that is not hallucinogenic, with the first cohort's top-line results indicating no significant adverse events [5]. Group 2: Executive Commentary and Stock Performance - Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, stated that the recruitment of the first patient at TASMC is a significant step that accelerates the global trial [6]. - The company's stock has seen a substantial decline of 88.97% year-to-date, with a 52-week price range of $0.15 to $2.18 and a market capitalization of $5.26 million [6].